Virtual Library

Start Your Search

Hiroaki Kodama

Author of

  • +

    P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.01-40 - Treatment of Super Elderly Patients for Non-Small Cell Lung Cancer in Japan (ID 13053)

      12:00 - 13:30  |  Author(s): Hiroaki Kodama

      • Abstract
      • Slides


      Japan is the one of the country with the longest life expectancy in the world; many elderly Japanese are treated for lung cancer. The number of people dying from lung cancer is consistently increasing, and nearly half of lung cancer patients are older than 75 years of age. It is said that 60% patients died of the lung cancer are patients over 75 years. Approximately half of lung cancers are found in advanced stage, and are treated by chemotherapy. However, many clinical trials of lung cancer treatment using conventional anticancer drugs are targeted toward patients younger than 70years old. No clear evidence on treatment for elderly patients over 80 years has been established.

      We conducted a retrospective analysis of patients over 80 years old who were diagnosed with advanced non small cell lung cancer.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      We retrospectively reviewed the outcome of patients over 80 years old who were diagnosed with advanced non small cell lung cancer between 2012 to 2016.

      4c3880bb027f159e801041b1021e88e8 Result

      48 patients were incorporated in the study; 26 were treated by chemotherapy (Median age 84years (80-89), 16 males), 22 were in BSC (Median age 84 years (80-96years), 13 males). 69%(18/26) of the treatment group were in Performance Status 0-1, compared to 18%(4/22) in the BSC group.(p=0.0005)

      Adenocarcinoma was the most common type in the treatment group(16/28), followed by Squamous cell carcinoma (7/28). Half of the treated patients were in stage Ⅳ, 6 cases were stageⅢb, and 6 cases stageⅢa.

      The median overall survival in treatment group was 378 days, median number of regimen conduced was 1 (average 1.37). In BSC group, it was difficult to follow until death, therefore comparison with the treatment group is not analyzed.

      8eea62084ca7e541d918e823422bd82e Conclusion

      It was suggested that the prognosis was prolonged by chemotherapy in the treatment group, compared to the previous chemotherapy trials for elderly patients. Chemotherapy should also be considered in super elderly patients over 80 years old, when he/she has good PS. However, regarding chemotherapy for the elderly patients with non small cell lung cancer, it is important to carefully consider adverse events.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.